Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bromocriptine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 0.96 |
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.96 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 1.00 |
| ▸ | MAPT | P10636 | 10/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
| ▸ | MEN1 | O00255 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | USP2 | O75604 | 5/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromocriptine SCHEMBL29893478 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL40559 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL29360283 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL2405616 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL23468147 | 0.98 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL3134317 | 0.98 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL9526627 | 0.98 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL8032620 | 0.98 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL19276395 | 0.98 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL25297 | 0.98 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3137065-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | Pharnext (FR) | 2017-03-08 | — | — | EP | disclosed |
| EP-3062782-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | Pharnext (FR) | 2016-09-07 | — | — | EP | disclosed |
| WO-2015165948-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | PHARNEXT (FR) | 2015-11-05 | — | — | WO | disclosed |
| EP-2914252-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | Pharnext (FR) | 2015-09-09 | — | — | EP | disclosed |
| WO-2015063140-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2015-05-07 | — | — | WO | disclosed |
| WO-2014068007-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2014-05-08 | — | — | WO | disclosed |
| EP-2156839-A1 | Method of treating movement disorders using barbituric acid derivatives | Taro Pharmaceutical Industries Ltd. (IL) | 2010-02-24 | — | — | EP | disclosed |
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |